1,2,5,6-Tetrahydro-3-(3-(5-oxohexyl)-1,2,5-thiadiazol-4-yl)-1-methylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1,2,5,6-Tetrahydro-3-(3-(5-oxohexyl)-1,2,5-thiadiazol-4-yl)-1-methylpyridine
• 英文别名: 1,2,5,6-Tetrahydro-3-(3-(5-oxohexyl)-1,2,5-thiadiazol-4-yl)-1-methylpyridin；6-[4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]hexan-2-one
• 化学式: C₁₄H₂₁N₃OS
• 分子量: 279.406
• InChiKey: XZYCHZSGUFBLJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  74.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1,2,5,6-tetrahydro-3-(3-(5-hydroxyhexyl)-1,2,5-thiadiazol-4-yl)-1-methylpyridine 、 1,5-己二醇 、 草酸氯化物 、 三乙胺 在 草酸 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 1,2,5,6-Tetrahydro-3-(3-(5-oxohexyl)-1,2,5-thiadiazol-4-yl)-1-methylpyridine
  参考文献：
  名称：

  Method of treating urinary bladder dysfunctions with

  摘要：

  本发明涉及一种治疗患有尿道膀胱功能障碍的哺乳动物的新方法。

  公开号：

  US05565475A1

文献信息

• Method of treating urinary bladder dysfunctions with
  申请人：——

  公开号：US05565475A1

  公开（公告）日：1996-10-15

  The present invention relates to a novel method for treating a mammal suffering from urinary bladder dysfunctions.

  本发明涉及一种治疗患有尿道膀胱功能障碍的哺乳动物的新方法。
• Method of treating gastrointestinal motility disorders
  申请人：Novo Nordisk A/S

  公开号：US05545638A1

  公开（公告）日：1996-08-13

  The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.

  本发明涉及一种治疗患有胃肠蠕动障碍的哺乳动物的新方法。
• Heterocyclic compounds
  申请人：Novo Nordisk A/S

  公开号：US05376668A1

  公开（公告）日：1994-12-27

  The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

  本发明涉及治疗活性的杂环化合物，一种制备这些化合物的方法以及包含这些化合物的药物组合物。这些新颖的化合物可用作哺乳动物前脑和海马体认知功能的刺激剂，特别适用于治疗阿尔茨海默病、严重疼痛症状和青光眼。
• Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound
  申请人：ELI LILLY AND COMPANY

  公开号：EP0709094A2

  公开（公告）日：1996-05-01

  The present invention provides the use of a compound wherein Z1 is oxygen or sulphur; R is hydrogen, halogen, amino, -NHCO-R, C₃₋₇-cycloalkyl, C₄₋₁₀-(cycloalkylalkyl), -Z-C₃₋₇-cycloalkyl optionally substituted with C₁₋₆-alkyl, -Z-C₄₋₁₀-(cycloalkylalkyl), -Z-C₄₋₁₀-(cycloalkenylalkyl), -Z-C₄₋₁₀-(methylenecycloalkyl-alkyl), -NH-R2, -NR2R3, -NH-OR2, phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X, R, -ZR, -SOR, -SO₂R, -Z-R-Z³-R³, -Z-R-Z³-R³-Z⁴-R⁴, -Z-RCO-R³, -Z-R-CO₂-R³, Z-R-O₂C-R³, -Z-R-CONH-R³, -Z-R-NHCOR³, -Z-R-X, -Z-R-Z³-X, wherein Z, Z³, and Z⁴ independently are oxygen or sulphur, and R, R³ and R⁴ independently are straight or branched C₁₋₁₅-alkyl, straight or branched C₂₋₁₅-alkenyl, straight or branched C₂₋₁₅-alkynyl, each of which is optionally substituted with halogen(s), -OH, -CN, -CF₃, -SH, -COOH, -NH-R, -NRR³, C₁₋₆alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, C₁₋₄-alkyl or C₁₋₄-alkoxy, and X is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C₁₋₆-alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group; and R⁵ and R⁶ may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C₁₋₅-alkyl, straight or branched C₂₋₅-alkenyl, straight or branched C₂₋₅-alkynyl, straight or branched C₁₋₁₀-alkoxy, straight or branched C₁₋₅-alkyl substituted with -OH, -OH, halogen, -NH₂ or carboxy; R¹ is hydrogen, straight or branched C₁₋₅-alkyl, straight or branched C₂₋₅-alkenyl or straight or branched C₂₋₅-alkynyl; or a pharmaceutically acceptable salt or solvate thereof; for the manufacture of a medicament for the treatment of anxiety.

  本发明提供了一种化合物的用途 其中 Z1 是氧或硫； R是氢、卤素、氨基、-NHCO-R、C₃₋₇-环烷基、C₄₋₁₀-(环烷基烷基)、-Z-C₃₋₇-环烷基任选被C₁₋₆-烷基取代、-Z-C₄₋₁₀-(环烷基烷基)、-Z-C₄₋₁₀-(环烯基)、-Z-C₄₋₁₀-(亚甲基环烷基)、-NH-R2、-NR2R3、-NH-OR2、苯基、苯氧基、苯甲酰基、苄氧羰基、四氢萘基、茚基、X、R、-ZR、-SOR、-SO₂R、-Z-R-Z³-R³、-Z-R-Z³-R³-Z⁴-R⁴、-Z-RCO-R³、-Z-R-CO₂-R³、Z-R-O₂C-R³、-Z-R-CONH-R³、-Z-R-NHCOR³、-Z-R-X、-Z-R-Z³-X，其中 Z、Z³、和 Z⁴ 独立地为氧或硫，而 R、R³ 和 R⁴ 独立地为直链或支链 C₁₋₁₅-烷基、直链或支链 C₂₋₁₅- 烷基、直链或支链 C₂₋₁₅- 烷炔基、其中每个都可选地被卤素、-OH、-CN、-CF₃、-SH、-COOH、-NH-R、-NRR³、C₁₋₆烷基酯、一个或两个苯基、苯氧基、苯甲酰基或苄氧基取代、苯甲酰基或苄氧羰基，其中每个芳香基团可任选被一个或两个卤素、-CN、C₁₋₄-烷基或 C₁₋₄-烷氧基取代，且 X 是含有 1 至 4 个 N、O 或 S 原子的 5 或 6 位杂环基团、O 或 S 原子或其组合，该杂环基团的碳原子或氮原子可选择被直链或支链 C₁₋₆-烷基、苯基、苄基或吡啶取代，或该杂环基团中的碳原子与氧原子一起形成羰基，或该杂环基团可选择与苯基融合；和 R⁵ 和 R⁶ 可出现在任何位置，包括噻二唑或噁二唑环的连接点，且各自为氢、直链或支链 C₁₋₅-烷基、直链或支链 C₂₋₅- 烷基、直链或支链 C₂₋₅- 烷炔基、直链或支链 C₁₋₁₀-烷氧基、被 -OH、-OH、卤素、-NH₂ 或羧基取代的直链或支链 C₁₋₅ 烷基；R¹ 是氢、直链或支链 C₁₋₅-烷基、直链或支链 C₂₋₅-烯基或直链或支链 C₂₋₅-炔基；或 其药学上可接受的盐或溶液；用于制造治疗焦虑症的药物。
• US35822
  申请人：——

  公开号：——

  公开（公告）日：——